nebratamig (GNC-035) / Biokin Pharma - LARVOL DELTA

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Oncology • Solid Tumor • PD-L1

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=3 | Active, not recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=40 ➔ 3

Enrollment change • Enrollment closed • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=33 | Active, not recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=58 ➔ 33

Enrollment change • Enrollment closed • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • PD-L1

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • PD-L1

GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2024 ➔ Oct 2024 | Trial primary completion date: Jun 2024 ➔ Oct 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • PD-L1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2023 ➔ Jun 2024 | Trial primary completion date: Nov 2023 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • PD-L1

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1/2 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1/2 trial • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Tetra-specific antibody GNC-035: guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies (AACR 2023) - "These results indicate GNC-035 has a therapeutic window of activity that is ROR1 dependent, spanning cytolytic activity, and IFN-γ release without a production of IL-6 and which is wider than that indicated by Blinatumomab in PBMC.Collectively, the GNC-035 represents a class of multi-specific and multi-modal immune cell engagers with potential to mediate ROR1+ cancer regression, overcome TCR-based immune escape and reverse T cell immune suppression in tumor microenvironment. The clinical phase I-b study of GNC-035 is under way in breast cancer and hematologic cancers and the available data exhibit strong signals of efficacy with acceptable tolerability."

Breast Cancer • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Solid Tumor • IFNG • IL6 • PD-L1 • ROR1

SystImmune to Present Data from Seven Preclinical Programs at the American Association of Cancer Research (AACR) Annual Meeting 2023 (PRNewswire) - "SystImmune...has announced that it will present data from seven preclinical programs in poster presentations at the American Association of Cancer Research (AACR) meeting....SystImmune will present its findings in several poster sessions at the AACR meeting, including 'Antibody Technologies', 'Therapeutic Antibodies, Including Engineered Antibodies', and 'Growth Factor Receptors as Therapeutic Targets'."

Preclinical • Oncology • Solid Tumor

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | N=29 ➔ 58

Enrollment change • Metastases • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | N=29 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Metastases • Trial withdrawal • Breast Cancer • Oncology • Solid Tumor • PD-L1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1; N=29; Recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1; N=29; Recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Breast Cancer • Oncology • Solid Tumor • PD-L1